Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Fostamatinib on Inflammatory Biomarkers in Hospitalized Patients With COVID-19.

Critical care explorations·2026
Same author

Monitoring What Matters: Artificial Intelligence, Inspiratory Effort, and Patient-Ventilator Interaction in the ICU.

Critical care medicine·2026
Same author

Multisite evaluation of automated electronic case report form data entry from electronic health records.

Journal of biomedical informatics·2026
Same author

Compassionate Extracorporeal Membrane Oxygenation Discontinuation: A Narrative Review and Practical Process Model for Reliable End-of-Life Care.

Healthcare (Basel, Switzerland)·2026
Same author

Genomic surveillance of human metapneumovirus in the United States, 2010-2025.

The Journal of infectious diseases·2026
Same author

Temperature Control After In-Hospital Cardiac Arrest: Outcomes From the Discover In-Hospital Cardiac Arrest Cohort.

Critical care medicine·2026

Related Experiment Video

Updated: May 10, 2026

In Vitro Assay to Evaluate the Impact of Immunoregulatory Pathways on HIV-specific CD4 T Cell Effector Function
09:26

In Vitro Assay to Evaluate the Impact of Immunoregulatory Pathways on HIV-specific CD4 T Cell Effector Function

Published on: October 15, 2013

14.0K

Resource Use in the Randomized Master Protocol for Immune Modulators for Treating COVID-19 (ACTIV-1 IM): A Secondary

Anne M Lachiewicz1, Miloni Shah2, Tatyana Der3

  • 1Division of Infectious Diseases, University of North Carolina, Chapel Hill, NC, USA.

CHEST Critical Care
|November 29, 2024
PubMed
Summary
This summary is machine-generated.

This study found that infliximab and abatacept, when added to standard COVID-19 pneumonia treatment, slightly reduced healthcare resource use. While infliximab showed broader benefits, both treatments demonstrated a decrease in hospital days and interventions.

Keywords:
COVID-19abatacepthospitalizationinfliximabresource utilizationsupplemental oxygenventilator

More Related Videos

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays
06:03

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays

Published on: September 20, 2024

1.2K
A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes
11:34

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes

Published on: April 11, 2025

190

Related Experiment Videos

Last Updated: May 10, 2026

In Vitro Assay to Evaluate the Impact of Immunoregulatory Pathways on HIV-specific CD4 T Cell Effector Function
09:26

In Vitro Assay to Evaluate the Impact of Immunoregulatory Pathways on HIV-specific CD4 T Cell Effector Function

Published on: October 15, 2013

14.0K
Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays
06:03

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays

Published on: September 20, 2024

1.2K
A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes
11:34

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes

Published on: April 11, 2025

190

Area of Science:

  • Immunology
  • Infectious Diseases
  • Health Services Research

Background:

  • Coronavirus disease 2019 (COVID-19) pneumonia significantly burdens healthcare systems.
  • Understanding interventions that reduce resource utilization is crucial for managing the pandemic.

Purpose of the Study:

  • To evaluate if infliximab or abatacept, as adjuncts to remdesivir and steroids, decrease healthcare resource utilization in hospitalized COVID-19 pneumonia patients.
  • To analyze the impact of these immunomodulators on various resource metrics over 28 days.

Main Methods:

  • Secondary analysis of the Accelerating COVID-19 Therapeutic Interventions and Vaccines Immunomodulator (ACTIV-1 IM) trial.
  • Compared infliximab and abatacept groups against a placebo group using proportional odds models.
  • Assessed days of hospitalization, ICU care, supplemental oxygen, ventilation, and ECMO.

Main Results:

  • Infliximab was associated with greater odds of being alive and free of all tested interventions compared to placebo.
  • Abatacept use showed greater odds of being alive and free of hospitalization and supplemental oxygen.
  • Both infliximab and abatacept demonstrated decreased healthcare resource utilization over 28 days, though absolute differences were modest.

Conclusions:

  • Infliximab and abatacept show potential in reducing healthcare resource utilization for COVID-19 pneumonia.
  • Further research may be needed to optimize the use of these immunomodulators to maximize clinical and resource-related benefits.